May 24, 2024 07:15 AM EDTUpdated 08:02 AM
R&D
Pharma

No­vo re­ports 're­al­ly pow­er­ful' car­dio, death risk re­duc­tion for semaglu­tide in kid­ney dis­ease

Katherine Lewin

News Reporter

No­vo Nordisk’s semaglu­tide cut the risk of ma­jor car­dio­vas­cu­lar events and death from mul­ti­ple caus­es in a Phase 3 study in­volv­ing pa­tients with type 2 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Au­toim­mune CAR-T da­ta dump: Kyver­na, Ca­balet­ta shares fall af­ter un­veil­ing ear­ly-stage re­sults

Up­dat­ed: Telix Phar­ma­ceu­ti­cals pulls Nas­daq list­ing plans just be­fore trad­ing was to start

Stephen Squin­to talks writ­ing checks and next-gen obe­si­ty drugs as JP Mor­gan clos­es first $500M+ biotech fund

Gilead can­cer drug ma­grolimab showed wor­ry­ing trends around death

BIO's new CEO takes a pa­tri­ot­ic piv­ot to win back Con­gress, push­ing in­dus­try to re­think Chi­na re­la­tion­ship

sponsored

De-risk­ing the pa­tient jour­ney in cell ther­a­pies: Six key con­sid­er­a­tions

A service from the Financial Times